Fractyl Health, formerly called Fractyl Laboratories, closed a $100m Series F financing to support the ongoing development of duodenal mucosal resurfacing (DMR) technology that addresses the root causes of type 2 diabetes, the Massachusetts company announced on 16 June.
“The [ongoing] emergence from the pandemic has created an opportunity for us to begin to accelerate our plans for advancing our clinical programs,” Fractyl